Global IgA Nephropathy Drugs Market - 2023-2030

Overview

Global IgA nephropathy drugs market reached US$ 120.1 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 436.4 million by 2030 exhibiting a CAGR of 18.1% during the forecast period (2023-2030).

The IgA nephropathy drugs market trends show rising product launches owing to the rising technologies and increasing research and development. IgA nephropathy drugs is a form of autoimmune disease that affects the kidneys and results in inflammation or kidney damage while clumps of antibodies accumulate there. Immunoglobulin A (IgA) and other antibody clumps harm the kidneys' glomeruli, which are small blood vessels that filter blood, leading the kidneys to release blood and protein into the urine.

Furthermore, rising adoption of IgA nephropathy drugs due to the rising availability of products and nephropathy incidence, an increase in the number of approved products in the market, and an increase in the research and development is driving up the IgA nephropathy drugs market size. The market is experiencing a growth demand for products from North America areas as a result of the rising advancements in this field. With significant competitors like Novartis AG, Chinook Therapeutics, Everest Medicines, and others actively operating in the market.

Dynamics

Rising research and development and novel product launches drive the growth of the IgA nephropathy drugs market

The majority of IgA production takes place at the mucosal surfaces of the gastrointestinal or respiratory tracts, however bone marrow plasma cells contribute a significant amount of the circulating IgA. Mucosal pathogens can be neutralized by IgA4, and several respiratory and gastrointestinal illnesses, including acute SARS-CoV-2 infection, have been linked to increased IgA responsiveness. Elevated serum IgA levels are a frequent occurrence in people with metabolic syndrome, diabetes, and IgA nephropathy.

Several novel products are being launched by the major players in the market leading to growth of market. For instance, on February 17, 2023, according to a report from Travere Therapeutics, Inc., FILSPARI (sparsentan) has received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat people with primary IgAN who are at risk for rapid disease progression and who have proteinuria, often defined as a urine protein-to-creatinine ratio (UPCR) of less than 1.5 g/g. The market is predicted to take the lead throughout the forecast period as a consequence of the aforementioned claims.

Rising collaborations and product pipeline by key players creates opportunities for the growth of the market

Major players are utilizing several strategic initiatives such as product launch, partnerships, mergers, partnerships, clinical trials among others for the growth of the market. For instance, on July 28, 2023, the BEYOND study, an important phase 3 clinical study evaluating the safety as well as the effectiveness of zigakibart (BION-1301), a possible disease-modifying anti-APRIL monoclonal antibody, has enrolled the first patient with IgA nephropathy (IgAN).

The BEYOND study's primary efficacy outcome compares the effectiveness of zigakibart to a placebo in reducing proteinuria as shown by changes in the urine protein to creatinine ratio (UPCR) between baseline and 40 weeks, according to Chinook Therapeutics, Inc., a biopharmaceutical business focused on the discovery, development, and marketing of precision medicines for kidney diseases.

Side effects associated with IgA nephropathy drugs will hamper the growth of the market

IgA nephropathy is managed by medical professionals with drugs and dietary adjustments. The medical professional may in few circumstances additionally recommend immunosuppressants, such as corticosteroids. But these drug type have potentially harmful side effects, like weight gain or immune system deterioration. To track the effectiveness of the drugs and the need for modifications, routine blood tests are employed. A higher likelihood of infection is the most important adverse effect of immunosuppressive drugs.

Segment Analysis

The global IgA nephropathy drugs market is segmented based on type, drug type, route of administrations, distribution channel and region.

Owing to high incidence, the primary IgA nephropathy from type segment accounted for approximately 63.7% of the IgA nephropathy drugs market share

The primary IgA nephropathy category held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in its incidence worldwide, amongst the population. The most typical autoimmune form of glomerulonephritis is Immunoglobulin nephropathy (IgAN), sometimes referred to as Berger's disease. The creation of pathogenic IgA1-containing antibody complexes is driven by an elevated level of galactose-deficient IgA1 and the formation of specific anti-glycan antibodies, according to a four-hit theory for the pathogenesis of IgAN.

The buildup causes the complement system along with mesangial cells to become active, releasing cytokines or extracellular matrix proteins. Given the aforementioned, glomerular function decline in IgAN is a result of persistent inflammation and fibrosis. Adult incidence is thought to be 25/1,000,000 year. IgAN is more prevalent among Asian populations than Caucasians (31/1,000,000 annually in France), with 45/1,000,000 cases per year in Japan.

Geographical Penetration

North America accounted for approximately 40.3% of the market share in 2022, owing to the strong presence of major players and increasing healthcare infrastructure investment

Due to the rising need for IgA nephropathy drugs for development purpose in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for IgA nephropathy treatment.

Increasing expenditure on healthcare and rising awareness among people, advancement of technologies for diagnosis and treatment, and increase in pharmaceutical business establishment across the region are also contributing to the growth of IgA nephropathy drugs market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available drugs alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various advanced products that are being utilized for providing better medications, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the IgA nephropathy drugs market include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Vera Therapeutics, MorphoSys AG, Otsuka Pharmaceutical, Alembic Pharmaceuticals Limited, Everest Medicines, Novartis AG and Alexion Pharmaceuticals, Inc. among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide IgA nephropathy drugs market. The growth of the global IgA nephropathy drugs market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type

• Primary IgA Nephropathy
• Secondary IgA Nephropathy

By Drug Type

• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Angiotensin Receptor Blockers (ARBs)
• Immunosuppressants
• Omega-3 Fatty Acids
• Diuretics
• Others

By Route of Administration

• Oral
• Parental
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On August 1, 2023, the Phase 3 NefIgArd study's China open-label extension (cOLE) has seen the last patient enrolled, according to Everest Medicines, a biopharmaceutical firm specializing in the research, production, and marketing of novel drugs and vaccines. All eligible participants who have successfully completed the NefIgArd study are eligible for an additional 9 months of Nefecon treatment as part of the cOLE study, which will assess the effectiveness and safety of prolonged and repeated Nefecon medication in patients having IgA nephropathy (IgAN).
• On March 12, 2023, positive topline results from the global, double-blind, randomized, placebo-controlled third phase clinical trial NefIgArd, which compared the effectiveness of Nefecon (TARPEYO/Kinpeygo (budesonide) extended-release capsules) to a placebo in patients having primary IgA nephropathy (IgAN), were released by Calliditas Therapeutics AB. The estimated glomerular filtration rate (eGFR) was the primary endpoint of the trial, and Nefecon demonstrated a highly statistically significant advantage over placebo across the two-year period of 9 months of treatment using Nefecon or placebo and 15 months of follow-up off drug.
• On June 17, 2023, the Phase 2b ORIGIN clinical study of atacicept for the management of IgA nephropathy (IgAN) met its primary as well as key secondary outcomes, with statistically noteworthy and clinically significant decreases in proteinuria and stabilizing of eGFR through week 36, according to Vera Therapeutics, Inc., a late-stage biotechnology business focused on creating and distributing transformative treatments for individuals with serious immunological diseases. The 60th European Renal Association (ERA) Congress featured a late-breaking presentation on the ORIGIN results for week 36.

Why Purchase the Report?

• To visualize the global IgA nephropathy drugs market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of IgA nephropathy drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global IgA nephropathy drugs market report would provide approximately 69 tables, 69 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies